RecruitingNCT04262492

International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs

Sponsor

Stéphane Zuily

Enrollment

500 participants

Start Date

Oct 21, 2020

Study Type

OBSERVATIONAL

Conditions

Thrombosis Antiphospholipid Syndrome Anticoagulants Causing Adverse Effects in Therapeutic Use

Summary

This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.

Eligibility

Inclusion Criteria4

Patient receiving a comprehensive information about the study, and not opposed to participate
Age ≥ 18 yo
Classification of definite APS according to revised Sapporo-Sydney criteria
Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months

Exclusion Criteria4

Incomplete revised Sapporo-Sydney criteria
No data regarding the recurrent thrombosis
Pregnant woman
Age \< 18 yo

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRivaroxaban

Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID

Locations(1)

Stéphane Zuily

Nancy, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04262492

Related Trials

Platelet Volunteers, Longitudinal and Multi-omic Study

NCT071374291 location

Non-invasive Coronary Thrombus Imaging to Define These Cause of Acute Myocardial Infarction

NCT061135101 location